Endocyte Appoints Mike Sherman as President and Chief Executive Officer
June 20, 2016 08:45 ET
|
Endocyte, inc
WEST LAFAYETTE, Ind., June 20, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...
Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2016 16:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., May 26, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...
Endocyte Reports First Quarter 2016 Financial Results
May 04, 2016 08:00 ET
|
Endocyte, Inc.
- Data from Phase 1 Dose Escalation Studies of EC1456 and EC1169 to be Presented at ASCO -- Expansion Phase of Trials in Targeted Patients Expected to Yield Efficacy Data in 2016 --...
Endocyte Announces First Quarter 2016 Earnings Conference Call
April 27, 2016 16:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., April 27, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 4th, at 8:30 a.m. EDT to...
Endocyte Announces Promising Preclinical Data for Application of SMDC Technology in CAR T Cell Therapy in Late-Breaking Abstract at American Association for Cancer Research (AACR) Annual Meeting 2016
April 19, 2016 09:01 ET
|
Endocyte, Inc.
Poster demonstrates novel approach to a universal T cell overcoming key challenges of current chimeric antigen receptor (CAR) technologies/therapies Potentially meaningful application of SMDC...
Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2016
April 11, 2016 16:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., April 11, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...
Endocyte Reports Fourth Quarter and Year End 2015 Financial Results and Provides Clinical and Pipeline Update
March 02, 2016 16:01 ET
|
Endocyte, Inc.
- EC1456 and EC1169 Advance in Phase 1 Dose Escalation Studies -- Expansion Phase of Trials in Targeted Patients Expected to Yield Efficacy Data in 2016 -- Two New Clinical Development...
Endocyte Announces Fourth Quarter and Full Year 2015 Earnings Conference Call
February 24, 2016 16:01 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, Mar. 2, at 4:30 p.m. EST to discuss...
Endocyte to Present at Upcoming Conferences
February 16, 2016 16:00 ET
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...
Endocyte Reports Third Quarter 2015 Financial Results and Provides Update on Clinical Progress
November 03, 2015 16:01 ET
|
Endocyte, Inc.
- Dose Escalation for EC1456 and EC1169 Advance in Phase 1 Studies -
- Conference Call Today at 4:30 p.m. EST -
WEST LAFAYETTE, Ind., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc....